HC Wainwright Has Positive Outlook of VERV FY2025 Earnings

Verve Therapeutics, Inc. (NASDAQ:VERV) – Analysts at HC Wainwright upped their FY2025 earnings estimates for shares of Verve Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($2.16) for the year, up from their previous forecast of ($2.38). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Verve Therapeutics’ current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Verve Therapeutics’ Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.68) EPS and Q4 2026 earnings at ($0.70) EPS.

Verve Therapeutics (NASDAQ:VERV) last posted its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The business had revenue of $32.98 million for the quarter, compared to analysts’ expectations of $7.13 million.

Other equities research analysts have also recently issued research reports about the stock. Cantor Fitzgerald upgraded shares of Verve Therapeutics from a “neutral” rating to an “overweight” rating in a research report on Tuesday, April 15th. Royal Bank of Canada decreased their price objective on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. William Blair reissued an “outperform” rating on shares of Verve Therapeutics in a research report on Friday, February 21st. Canaccord Genuity Group increased their price objective on Verve Therapeutics from $32.00 to $39.00 and gave the company a “buy” rating in a report on Tuesday, April 15th. Finally, Guggenheim boosted their price target on Verve Therapeutics from $18.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, April 15th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $25.75.

Verve Therapeutics Stock Performance

Shares of VERV stock opened at $4.61 on Wednesday. The stock’s fifty day moving average is $4.71 and its 200-day moving average is $5.84. Verve Therapeutics has a 52 week low of $2.86 and a 52 week high of $9.31. The stock has a market capitalization of $410.95 million, a PE ratio of -1.87 and a beta of 1.82.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. IFP Advisors Inc grew its holdings in shares of Verve Therapeutics by 823,700.0% during the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock worth $47,000 after purchasing an additional 8,237 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in Verve Therapeutics during the fourth quarter worth about $50,000. KFG Wealth Management LLC acquired a new stake in Verve Therapeutics during the first quarter worth about $46,000. Cambridge Investment Research Advisors Inc. bought a new position in Verve Therapeutics in the 1st quarter valued at about $47,000. Finally, E Fund Management Co. Ltd. acquired a new position in shares of Verve Therapeutics in the 1st quarter valued at approximately $48,000. 97.11% of the stock is owned by institutional investors and hedge funds.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.